ATE404183T1 - AGENT CONTAINING ERGOLIN FOR TRANSDERMAL APPLICATION - Google Patents
AGENT CONTAINING ERGOLIN FOR TRANSDERMAL APPLICATIONInfo
- Publication number
- ATE404183T1 ATE404183T1 AT04735452T AT04735452T ATE404183T1 AT E404183 T1 ATE404183 T1 AT E404183T1 AT 04735452 T AT04735452 T AT 04735452T AT 04735452 T AT04735452 T AT 04735452T AT E404183 T1 ATE404183 T1 AT E404183T1
- Authority
- AT
- Austria
- Prior art keywords
- ergolin
- agent containing
- transdermal application
- tert
- stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a transdermal therapeutic system containing ergolin compounds, preferably lisuride, in which the ergolin compound is stabilized. The oxidation-sensitive ergolin compound is stabilized by a combination of at least one liposoluble, free radical-scavenging antioxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl metoxy phenol, tocopherol or ubiquinone and a basic polymer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10341317A DE10341317B4 (en) | 2003-09-03 | 2003-09-03 | Transdermal therapeutic system (TTS) for administration of ergoline compounds except pergolide |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE404183T1 true ATE404183T1 (en) | 2008-08-15 |
Family
ID=34223453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04735452T ATE404183T1 (en) | 2003-09-03 | 2004-05-30 | AGENT CONTAINING ERGOLIN FOR TRANSDERMAL APPLICATION |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070134309A1 (en) |
EP (1) | EP1660054B1 (en) |
JP (1) | JP2007504257A (en) |
AT (1) | ATE404183T1 (en) |
AU (1) | AU2004271679B2 (en) |
CA (1) | CA2504885A1 (en) |
DE (2) | DE10341317B4 (en) |
DK (1) | DK1660054T3 (en) |
ES (1) | ES2311825T3 (en) |
HK (1) | HK1086742A1 (en) |
NZ (1) | NZ546178A (en) |
PL (1) | PL1660054T3 (en) |
PT (1) | PT1660054E (en) |
SI (1) | SI1660054T1 (en) |
WO (1) | WO2005025546A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
JP5037831B2 (en) * | 2006-02-15 | 2012-10-03 | 久光製薬株式会社 | External patch for improving cohesion and sustained release |
DE102006013307B3 (en) * | 2006-03-21 | 2007-10-04 | Ergonex Pharma Gmbh | Terguride / proterguride for the treatment of chronic pain |
DE102006048130A1 (en) * | 2006-10-06 | 2008-04-10 | Axxonis Pharma Ag | Transdermal therapeutic system with biphasic release profile |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797405A (en) * | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
US5229129A (en) * | 1989-07-12 | 1993-07-20 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
US5674875A (en) * | 1993-05-04 | 1997-10-07 | Eli Lilly And Company | Method of blocking human 5-hydroxytryptamine-2 receptors |
US6572879B1 (en) * | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
DE19626621A1 (en) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Plaster for transdermal application of pergolide |
US6623752B1 (en) * | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
GB9711043D0 (en) * | 1997-05-29 | 1997-07-23 | Ciba Geigy Ag | Organic compounds |
DE19821788C1 (en) * | 1998-05-15 | 1999-12-02 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system (TTS) containing pergolide |
DE10054713C2 (en) * | 1999-11-29 | 2002-07-18 | Lohmann Therapie Syst Lts | Transdermal therapeutic systems with improved stability and a method for their production |
DE10043321B4 (en) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition |
CA2443128A1 (en) * | 2001-03-30 | 2002-10-10 | Debra A. Martin | Transdermal delivery of pergolide |
US20040120995A1 (en) * | 2002-04-01 | 2004-06-24 | Martin Debra A | Transdermal delivery of pergolide |
-
2003
- 2003-09-03 DE DE10341317A patent/DE10341317B4/en not_active Expired - Fee Related
-
2004
- 2004-05-30 SI SI200430854T patent/SI1660054T1/en unknown
- 2004-05-30 CA CA002504885A patent/CA2504885A1/en not_active Abandoned
- 2004-05-30 PL PL04735452T patent/PL1660054T3/en unknown
- 2004-05-30 DK DK04735452T patent/DK1660054T3/en active
- 2004-05-30 JP JP2006525610A patent/JP2007504257A/en active Pending
- 2004-05-30 WO PCT/DE2004/001133 patent/WO2005025546A1/en active IP Right Grant
- 2004-05-30 AT AT04735452T patent/ATE404183T1/en not_active IP Right Cessation
- 2004-05-30 PT PT04735452T patent/PT1660054E/en unknown
- 2004-05-30 AU AU2004271679A patent/AU2004271679B2/en not_active Ceased
- 2004-05-30 NZ NZ546178A patent/NZ546178A/en unknown
- 2004-05-30 US US10/570,262 patent/US20070134309A1/en not_active Abandoned
- 2004-05-30 ES ES04735452T patent/ES2311825T3/en not_active Expired - Lifetime
- 2004-05-30 DE DE502004007855T patent/DE502004007855D1/en not_active Expired - Fee Related
- 2004-05-30 EP EP04735452A patent/EP1660054B1/en not_active Expired - Lifetime
-
2006
- 2006-06-13 HK HK06106736.0A patent/HK1086742A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2007504257A (en) | 2007-03-01 |
SI1660054T1 (en) | 2008-12-31 |
EP1660054B1 (en) | 2008-08-13 |
ES2311825T3 (en) | 2009-02-16 |
PT1660054E (en) | 2008-10-08 |
WO2005025546A1 (en) | 2005-03-24 |
EP1660054A1 (en) | 2006-05-31 |
HK1086742A1 (en) | 2006-09-29 |
NZ546178A (en) | 2008-12-24 |
AU2004271679B2 (en) | 2007-09-20 |
US20070134309A1 (en) | 2007-06-14 |
CA2504885A1 (en) | 2005-03-24 |
DK1660054T3 (en) | 2008-11-17 |
AU2004271679A1 (en) | 2005-03-24 |
DE502004007855D1 (en) | 2008-09-25 |
DE10341317A1 (en) | 2005-03-31 |
DE10341317B4 (en) | 2008-10-23 |
PL1660054T3 (en) | 2009-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105387T1 (en) | SUBSTITUTED 2-DIALKYLAMINOALKYLBIFINTHIUM DERIVATIVES | |
SE0301700D0 (en) | Novel compounds | |
EA201000089A1 (en) | APPLICATION OF HOMO- AND COPOLYMERS TO STABILIZE THE COMPOSITIONS OF ACTIVE INGREDIENTS | |
DK1615646T4 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE | |
ATE448777T1 (en) | AGENT FOR TRANSDERMAL ADMINISTRATION OF NICOTINE | |
DE60205749D1 (en) | ORAL DRUG COMPOSITIONS TO BE APPLIED WITH A TAXED ACTIVE SUBSTANCE | |
EA201170772A1 (en) | ORGANIC COMPOUNDS | |
SG145715A1 (en) | Mitoquinone derivatives used as mitochondrially targeted antioxidants | |
BRPI0417578A (en) | endoparasiticidal compositions for topical application | |
PA8624601A1 (en) | MACROLIDES AND METHODS TO PRODUCE THE SAME | |
BRPI0515721A (en) | use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination | |
ES2328496T3 (en) | 1,4,8-TRIAZA-ESPIRO (4,5) DECAN-2-ONA SUBSTITUTED COMPOUNDS. | |
CL2007002106A1 (en) | LIQUID MONOPHASIC COMPOSITION THAT INCLUDES 3 ANTIOXIDANTS, 1st, SYNTHETIC PHENOLIC COMPOUND THAT IS NOT DERIVED FROM QUINOOLINE, 2nd, PHENOLIC, ASCORBIC ACIDES, TOCOPHEROLS, LECITINE, BIOFLAVONOID OR THERPENOLINE, OR 3; | |
ATE401863T1 (en) | NEW VISCOELASTIC COMPOSITION COMPRISING ALGINATE AND VITAMIN E TPGS OR TPGSA | |
BRPI0413742A (en) | mitoquinone derivatives used as mitochondrially targeted antioxidants | |
UY27852A1 (en) | DIFENILAZATIDINONAS CATIONICAMENTE REPLACED, PROCEDURE FOR PREPARATION, MEDICINES THAT UNDERSTAND THESE COMPOUNDS AND THEIR USE. | |
HK1086742A1 (en) | Agent containing ergolin for transdermal application | |
DE602007012471D1 (en) | FILLED PLASTIC COMPOSITION | |
SE0302546D0 (en) | New compounds | |
ATE498600T1 (en) | INDENE DERIVATIVES AS PHARMACEUTICALS | |
PA8605101A1 (en) | 4- (AMINOMETIL) -PIPERIDIN BENZAMIDAS AS AN 5GT4 ANTAGONIST | |
TW200503737A (en) | Water soluble wortmannin derivatives | |
DE602004026410D1 (en) | SYNDICOTACTIC PROPYLENE POLYMER CONTAINING COMPOSITION | |
EA200600590A1 (en) | PHARMACEUTICAL COMPOSITIONS OF MODAFINIL WITH MODIFIED DELIVERY | |
DE602004019083D1 (en) | OXYGEN BARRIER FORMULATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REN | Ceased due to non-payment of the annual fee |